AstraZeneca to Withdraw Low-Dose Zoladex from Australian Market, Raising Concerns for Breast Cancer and Endometriosis Patients
核心洞察
AstraZeneca will remove goserelin 3.6mg implant (Zoladex) from Australia's PBS and private market in November 2026, citing commercial reasons unrelated to safety or efficacy.
An estimated 8,600 patients received the low-dose formulation in Q1 2026, with the drug used for hormone-sensitive breast cancer (搜索), endometriosis (搜索), and fertility preservation.
The PBAC has warned the withdrawal will result in "unmet clinical need," while AstraZeneca plans a six-month free access program for patients without alternatives.
AstraZeneca has confirmed it will withdraw its low-dose goserelin 3.6mg implant, marketed as Zoladex, from the Australian market effective November 1, 2026. The decision affects both the Pharmaceutical Benefits Scheme (PBS) listing and private market availability, leaving thousands of patients who rely on the monthly hormone-suppressing therapy facing an uncertain treatment future.
The drug, delivered as a small pellet injected under the skin once monthly, works by stopping the ovaries from producing oestrogen. It is prescribed to slow the growth of hormone-sensitive breast cancers, reduce recurrence risk, and manage endometriosis (搜索) symptoms. A higher 10.8mg dose administered every 12 weeks will remain on the PBS, but is currently approved in Australia only for prostate cancer (搜索).
Patient Impact and Clinical Concerns
An estimated 8,600 patients were dispensed the 3.6mg formulation in the first three months of 2026, according to figures from the Department of Health. The Pharmaceutical Benefits Advisory Committee (PBAC), which advises the federal government on PBS listings, has stated that removal of the drug from the market would result in "unmet clinical need."
Vicki Durston, director of policy advocacy and support services at Breast Cancer (搜索) Network Australia (BCNA), described the anxiety this has created among patients: "They're already living with fear of recurrence or fear of progression."
Kate Hardman, a 41-year-old mother of three with stage 4 metastatic breast cancer (搜索) who has been using Zoladex 3.6mg since 2023, called the decision "cruel." She said, "It's kind of shocking because for me, that's life-saving. For a lot of women, that's saving their fertility, so to have that just taken away is cruel."
Clinical oncologist Rachel Dear at St Vincent's Hospital acknowledged that while AstraZeneca's planned access program provided some reassurance, her patients remained worried. "Being a pre-menopausal woman with early breast cancer (搜索) going into medical menopause is already a huge overlay on already difficult treatment," Dr Dear said.
The Company's Position
AstraZeneca has attributed the withdrawal to "commercial reasons," with a spokesperson stating the removal was "a global AstraZeneca decision to reduce the dose options available in some countries" and not related to the product's safety or efficacy. The company declined to provide additional context or specify which other countries have been affected.
Under questioning from Independent senator David Pocock in Senate estimates, health department official Duncan McIntyre confirmed: "We've been in discussions with AstraZeneca and a range of other companies about the retention, but the company has advised that they are removing that item from a number of markets, including Australia, and that that's been a commercial decision."
Potential Factors Behind the Decision
Nial Wheate, professor of pharmaceutical chemistry at Macquarie University, suggested pricing dynamics may play a role, while noting that the federal government's negotiation stance is essential for PBS sustainability. "The PBS costs the Australian government billions of dollars a year, and if they weren't really strong in their negotiations, the PBS would not be affordable for Australians," Professor Wheate said.
The Australian market represents approximately 2.1% of total global demand for medicines. In 2025, there were nearly 100,000 scripts for the low-dose medication across the country. For AstraZeneca, consolidating from two products to one may offer manufacturing efficiencies and cost savings.
Transition Pathways and Alternatives
AstraZeneca has committed to providing free access to the 3.6mg implant in Australia for an initial six months for patients "without alternative treatment pathways." The company stated: "We are working urgently to provide more information about the Zoladex Access Program to clinicians. Patients should consult their clinicians about their future treatment options."
The higher-dose 10.8mg formulation remains available, and the ABC understands that PBAC will likely consider an application for expansion of its PBS listing for breast cancer (搜索) at a meeting in July. Dr Dear expressed hope for this outcome but cautioned that "it was unclear whether the longer-acting dose was the gold standard for all patients."
For breast cancer (搜索) patients, more than 90 different chemotherapy treatment plans exist, with only three requiring Zoladex specifically. For endometriosis (搜索), alternative hormone treatments including contraceptives and progestogen tablets may serve as suitable replacements. Prostate cancer (搜索) patients, who have access to over 20 different medicine combinations, are unaffected by the withdrawal since the 10.8mg dose remains PBS-listed for their indication.
A health department spokesperson emphasized that "sponsors are private entities that make their own commercial decisions regarding their products and cannot be compelled by the government to continue to list or delist a product on the PBS."